Biolight 2025: The Raise Bought Time, But Value Still Needs Proof

Company Introduction

At first glance, Biolight can look like a tiny listed shell with a decent cash box and very little leverage. That is only half right. In practice, Biolight is an ophthalmology holding company that sits on a basket of portfolio assets spread across research, regulatory work, pilots and initial sales. Its current economics are therefore not driven by recurring revenue. They are driven by the ability to convert scientific, regulatory and commercial milestones into financing, partnership, listing or exit events.

That is also the right way to read 2025. The September 2025 public raise bought the company time, and the filing says management believes the company has sufficient resources, based on a forecast budget, for at least 24 months from the balance-sheet date. At the same time, the auditor still highlights the fact that the company has no activities generating positive revenue and cash flow. These two statements do not contradict each other. They say the bottleneck has moved: this is no longer primarily an immediate parent-company survival question. It is now a portfolio-proof question.

What is actually working now? At the solo level, Biolight ended 2025 with cash, short deposits and marketable securities of NIS 20.539 million. At the group level, current assets stood at NIS 24.402 million and equity reached NIS 39.111 million, about 92% of the balance sheet. DiagnosTear already has CE and Israeli approval for dry eye, Peripherex has an FDA-cleared product that has begun early clinic rollout, Modifeye reported positive human feasibility results, and OCUVIA already has dedicated management and an explicit financing or listing ambition.

What is still not clean? In 2025 the company reported zero revenue, a net loss of NIS 16.910 million, and operating cash outflow of NIS 10.854 million. The stronger balance sheet came from capital markets, not from operations. In other words, anyone looking only at the cash balance misses the fact that most of Biolight's value still sits in layers that need more time, more money and more proof.

There is also a practical actionability constraint here. This is a small-cap stock, liquidity is not deep, and meaningful short interest does not exist. That means the shares are likely to react more to sharp proof events or disappointments than to a gradual improvement in reported earnings.

The quick economic map looks like this:

This chart matters because it shows what the cash box really is. Most of current assets were not generated by operations. They were parked in marketable securities and short deposits after the capital raise. That expands reaction time, but it does not solve the value-creation question.

Events And Triggers

The first trigger: September 2025 changed the company's tone. Biolight issued 4,358,100 ordinary shares together with two public warrant series and received roughly NIS 19.6 million net. That is the event that bought it time. Without that raise, 2026 would have opened as a much tighter funding story.

The second trigger: OCUVIA became the flagship portfolio move in 2026. The company is trying to combine ORX and ViSci under one umbrella, it hired a CEO and COO, and it has started efforts toward a financing or listing process in the US. This matters because it could turn two separate development platforms into one capital-markets story. The other side is just as clear: the filing states explicitly that there is no certainty the move will actually happen, when it will happen, or on what terms.

The third trigger: Modifeye is the newest and sharpest option in the portfolio, but also one of the farthest from commercialization. In July 2025 the company received positive final results from a human feasibility study based on 40 tear samples, including 30 AMD samples and 10 healthy controls. Biolight has an option for an exclusive Harvard license, expects to hold about 80% in the company once formed, and notes that its own net investment in the study was only NIS 492 thousand because a global pharma company funded the rest of the spend. That is good as an early proof of capital efficiency. It is still not a product.

The fourth trigger: DiagnosTear is currently the asset closest to connecting science, regulation and capital markets. It completed a private financing of about NIS 2.1 million in Canada in 2025, Biolight now holds about 44%, and Biolight receives annual management fees of NIS 720 thousand from it. At the same time, DiagnosTear already has CE and Israeli approval for the dry-eye product, while the red-eye product is still in the trial-and-validation stage. So this is a platform that sits closer to commercialization than the rest, but is still not at the point where it can fund itself or the parent.

The fifth trigger: March 2026 added an important governance signal. The company called a meeting to approve 110 thousand options and 105 thousand RSUs for the CEO. Two thirds of the RSUs vest only if market cap reaches NIS 50 million and NIS 70 million for 20 consecutive trading days. This is not just a compensation decision. It is a clear sign that the company itself sees the next phase as a market-value test, not only a lab-progress test.

Efficiency, Profitability And Competition

The easiest mistake at Biolight is to read the income statement as if this were a normal operating company. That is a mistake. In 2025 the right question is not whether operating margins improved. The real question is how much of the loss comes from science, how much comes from the corporate layer, and how much comes from valuation noise.

The first point is that the company still does not have a recurring revenue engine. Revenue in 2025 was zero, versus NIS 219 thousand in 2024, because Eye Optima informed the company that there were manufacturing problems in the LipiTear product and there was no revenue in the year. So any "product portfolio" reading must start from the simple fact that there is still no recurring revenue layer carrying the story.

The second point is that the expense mix moved toward the corporate and capital-markets layer. Research and development expense rose to NIS 5.056 million from NIS 3.674 million, but general and administrative expense rose even more, to NIS 9.680 million from NIS 6.353 million. That is unusual for a small life-sciences name, and the filing explains why: 2025 included the first full year of DiagnosTear as a Canadian public company, while stock-based compensation jumped to NIS 3.908 million from only NIS 382 thousand a year earlier.

This chart makes the key point visible: in 2025 Biolight spent more on general and administrative expense than on research and development. That does not mean the science weakened. It means the public-company structure of the group, together with aggressive equity compensation, began to weigh on the P&L before revenue arrived.

Even the loss itself is not clean. Alongside an operating loss of NIS 16.584 million, the company recorded a fair-value loss of NIS 1.377 million. Most of that came from a roughly NIS 1.49 million reduction in the value of Sanoculis, partly offset by a gain of about NIS 113 thousand in AEYE. In addition, the company's share of Peripherex losses was NIS 463 thousand. So the bottom line is a mix of operating burn, model-based marking of non-traded assets, and losses from an associate.

This chart shows why "there is value" and "there is cash" are not the same thing. Biolight does have a meaningful non-cash holdings layer, but part of it is marked at level-3 fair value, part is carried under the equity method, and part sits inside SAFE agreements whose conversion timing is not under the company's control.

On competition, the company is effectively admitting in several assets that the market is crowded, regulatory, and dependent on larger external players. DiagnosTear still lacks a wide reimbursement and adoption path. Peripherex has FDA clearance, but the question is whether the pilot phase becomes broader commercialization. At OCUVIA and Modifeye, competition is measured less against current commercial products and more against time, money and the ability to find the right partner. In Biolight's case, the real 2026 competition is therefore not only other companies. It is also cash burn and capital-markets fatigue.

Cash Flow, Debt And Capital Structure

To read Biolight correctly, the cash framing needs to be explicit. The right frame here is all-in cash flexibility. This is not yet a company that should be assessed through normalized recurring cash generation. It should be assessed through how much time and balance-sheet room are left after the actual cash uses.

On that basis, 2025 looks like this: operating cash flow was negative NIS 10.854 million, investing cash flow was negative NIS 16.174 million, and only financing cash flow, positive NIS 21.369 million, partly offset the picture. Cash and cash equivalents ended the year at NIS 3.978 million, but the group also held NIS 18.465 million in marketable securities and NIS 1.211 million in short-term deposits.

The conclusion is straightforward: the stronger balance sheet in 2025 was not built by operations. It was built by capital markets. The public raise at the parent contributed NIS 19.574 million, while DiagnosTear contributed another NIS 2.153 million from share issuance and NIS 247 thousand from option exercise. That is not a criticism. It is an accurate description of the phase the company is in.

At the balance-sheet level, the picture is actually light. Total current and non-current liabilities together were only NIS 3.303 million. Of that, NIS 1.060 million related to the Innovation Authority grant liability and NIS 772 thousand related to leases. In the classic leverage sense, the company is barely burdened, and equity is high relative to the size of the balance sheet. But that too needs a caveat: equity is not a funding bridge. Most of the non-cash value layer still requires a liquidity event or commercialization before it becomes accessible.

That is why the most important number sits at the solo level. According to the board report, the company had NIS 20.539 million of cash, short deposits and marketable securities at the end of 2025. That is the cash box that genuinely buys time for the parent company.

There is also an important capital-structure message. The number of issued shares almost doubled, from 4,657,836 at the end of 2024 to 9,047,603 at the end of 2025. The 2025 filing still included two public warrant series, but by the latest market snapshot included in the local evidence, early April 2026, only Series 10 remained traded. Its exercise price is NIS 7.5, while the share price was NIS 2.70. So the remaining public warrant is not a near-term financing bridge. It is an option on a rerating, not an immediate source of cash.

Outlook

Before getting into the details, four core findings need to be fixed in place:

• First: 2026 opens as a proof year, not as a funding-collapse year. Management speaks about at least 24 months of runway, but the auditor still highlights the lack of positive revenue and cash flow and the dependence on raises, realizations or strategic partnerships.
• Second: the main test of 2026 will not come from the consolidated income statement. It will come from whether one or more portfolio assets can move from a milestone to a real financing or commercialization event.
• Third: DiagnosTear and Peripherex are the assets closest to commercial proof, but even they are still far from generating material cash for the parent.
• Fourth: the future capital layer that appealed to investors in September 2025 weakened after March 2026, because Series 9 already reached its last exercise date and only Series 10 remains out of the money.

What has to happen at OCUVIA and Modifeye

OCUVIA and Modifeye are the two options that could change the read on Biolight relatively quickly, but for different reasons. OCUVIA could turn two development platforms into one financing story. Modifeye could turn a fresh scientific result into a new subsidiary with a license, management and partners. In both cases, value will not be created by another presentation alone. It will only be created if 2026 brings a clear external event.

The company itself gives a partial quantitative frame for that. In 2026 it expects roughly USD 0.5 million of investment into Modifeye, and the filing speaks about a minimum investment of about NIS 3.2 million in OCUVIA. Those numbers do not erase the cash box on their own, but they clarify priorities: even after the raise, resources are still finite.

What has to happen at DiagnosTear and Peripherex

At DiagnosTear, 2026 is supposed to answer whether the company knows how to move beyond the lab. The goals section includes efforts to sign distribution agreements for the dry-eye product in Europe, the UK and East Asia, while also trying to validate the FDA regulatory roadmap for the red-eye product, produce about 3,000 tests and start external studies, subject to sufficient financing. This is no longer a pure development stage. It is the stage where the market begins to ask whether there is a real revenue path.

At Peripherex, the story is simpler but sharp. The product is FDA-cleared, it has Israeli approval, and patients are already using it in a limited number of clinics. The question is not whether the technology exists. The question is whether the company can turn early adoption into broader commercialization and secure enough reimbursement and use to justify the investment layer.

This chart explains why 2026 is a proof year. Even after the raise, more activities still need cash than activities that return it.

What the market is likely to measure at the parent level

The first thing the market is likely to measure is not net profit. It is the rate at which solo liquidity is consumed relative to the timetable of milestones. The second thing is whether management can focus capital and attention around a small number of assets with real value-creation potential, rather than continuing to spread the cash across too many parallel options.

The third question is whether the company has truly moved from "emergency financing mode" to "path selection mode." The positive indication is that the filing now speaks about 24 months, about setting up Modifeye, about the OCUVIA combination and about commercialization objectives. The cautious indication is that the activity is still revenue-light and its dependence on capital markets has not disappeared. It has only been deferred.

How 2026 should really be read

The right name for the coming year is a proof year. Not a breakout year, because there is still no product carrying the group economically. Not a reset year, because the raise did buy time. It is a year in which each asset has to prove something different: OCUVIA has to show that it can approach financing or listing, Modifeye has to show that the study can become a funded platform, DiagnosTear has to show a commercialization path, and Peripherex has to show adoption.

Risks

The first risk is that cash bought time, not a business model

Even after the raise, the company remains dependent on external sources. If the 2026 milestones do not turn into financing, licensing, partnership or commercialization events, the discussion will move back toward dilution.

The second risk is that paper value continues to run ahead of accessible value

AEYE, Sanoculis, Revital Vision and Trisee sit inside an asset layer that is either model-based or event-based rather than cash-generating for the parent. In 2025 the company already showed how a Sanoculis markdown alone erased about NIS 1.49 million from earnings, while Trisee continues to be marked at zero. That matters because Biolight can look rich or cheap on asset value while shareholders still live on cash, not on an OPM model.

The third risk is that the layer closest to commercialization is still not close enough

DiagnosTear, Peripherex and Revital are the assets with the strongest commercial smell, but none of them currently acts as a real revenue anchor for the parent. DiagnosTear still needs approvals and distribution, Peripherex is still in rollout and reimbursement work, and Revital is held through a SAFE whose conversion timing is outside the company's control.

The fourth risk is regulatory and clinical, not only financial

The company says explicitly that the war affected the duration of studies and the pace of participant recruitment. In DiagnosTear, slower participant recruitment in the red-eye trial was explained, among other factors, by staffing shortages at medical centers due to the war. That is a reminder that at Biolight every regulatory or clinical delay is also a financing delay.

The fifth risk is market actionability

Thin liquidity and negligible short interest are not necessarily negative in themselves, but they do mean the stock can react more abruptly to single events. In that kind of setup, one disappointment in a central asset can damage confidence faster than it would in a larger and more diversified company.

Conclusions

Biolight ends 2025 in a better position than the one in which it entered the year, but still without an asset capable of carrying the group economically. The public raise, the solo liquid assets and the relatively light balance sheet bought it time. The question now is what the company does with that time. In the short to medium term, the market will focus less on the reported loss and more on whether one of the core assets can move from a milestone to a real value event.

Current thesis: Biolight bought time and flexibility in 2025, but the next step in shareholder value will come only if the portfolio moves from scientific or regulatory proof to financing, partnership or commercialization proof.

What changed versus the reading that was possible before the raise? Before September 2025 it was easy to read the company mainly as a funding problem. After the raise, that is only partial. Today the central issue is not whether it has time, but whether it can convert that time into a value-creating move.

The strongest counter-thesis is that the company is still too far from any real monetization event, so even a NIS 20.5 million solo cash box is not enough to justify such a broad platform story. On that view, 2026 could still look like another year of progress without commercialization, which would push dilution back to the center.

What could change the market's near-term reading? A financing or listing step at OCUVIA, a signed license and funded setup at Modifeye, clear commercialization progress at DiagnosTear or Peripherex, or, on the other side, rapid cash burn without any external value event.

Why does this matter? Because at Biolight the gap between "there are assets" and "there is accessible value" is especially large. If you understand that gap, you understand the stock.

Over the next 2 to 4 quarters, the thesis strengthens if OCUVIA moves toward financing, if Modifeye signs a license and is formed with clear funding, and if DiagnosTear or Peripherex show a more convincing commercialization path. It weakens if the cash box is consumed without an external event, if trials continue to slip, or if capital markets stay closed exactly when the company needs the next step.